Sign Up
Stories
Anti-Obesity Meds' Impact on Allurion Program
Share
Amgen's Obesity Prospects and Q4 Results...
Biden's $35 Insulin Price Cap
Biopharma Innovations in Obesity and Mus...
FDA Finds No Preliminary Link Between Oz...
FDA Warns of Counterfeit Ozempic
Innovative REGN4461 for Lipodystrophy Ma...
Overview
API
New research highlights the positive impact of anti-obesity medications, particularly GLP-1s, on the Allurion Program, with the global market for anti-obesity medications projected to reach $100 billion by 2030. The research indicates a positive influence of GLP-1 growth on Allurion Program awareness among healthcare professionals and patients. Allurion's CEO, Shantanu Gaur, emphasized the potential of the Allurion Program as an ideal first-line treatment for combating obesity.
Ask a question
How can the increasing demand for anti-obesity medications impact the healthcare industry and patient access to treatments?
How might the growing interest in anti-obesity medications influence the development and adoption of other healthcare interventions?
What are the potential implications of the Allurion Program's success as a first-line treatment for obesity?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage
Dec